Showing results for:
Dexamethasone, hydrocortisone, methylprednisolone and prednisone are FDA approved corticosteroids that are used to treat many medical problems, including some kinds of cancer.
Decadron ®
Cytarabine is FDA approved to prevent and treat leukemia that has spread to the meninges (the three membranes that cover the brain and spinal cord). It is also FDA approved for use with other drugs to treat acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. This medicine may cause a temporary loss of hair in some people. After treatment with cytarabine has ended, normal hair growth should return.Liposomal cytarabine (DepoCyt®) is given by intrathecal injection. It is FDA approved to treat lymphoma that has spread to the meninges.
Cytosar-U® Cytosine arabinoside Ara-C Cytarabine Liposomal cytarabine DepoCyt®
Dacarbazine is used to treat people who have Hodgkin lymphoma as a second-line therapy when used in combination with other agents and is also used as initial therapy for some patients with Hodgkin lymphoma. It may cause a temporary loss of hair in some people. After treatment with dacarbazine has ended, normal hair growth should return.
DTIC-Dome® Dacarbazine
Daratumumab is FDA approved for the treatment of adult patients with multiple myeloma:In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapyIn combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplantIn combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplantIn combination with bortezomib and dexamethasone in patients who have received at least one prior therapyIn combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor As monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
Darzalex® Daratumumab
Daratumumab and hyaluronidase-fihj
Darzalex Faspro® is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, and is indicated for the treatment of adult patients with:Multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplantMultiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapyMultiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplantMultiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapyMultiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitorMultiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.Light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Limitations of Use:Darzalex Faspro is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials
Darzalex Faspro® Daratumumab and hyaluronidase-fihj
Darbepoetin alfa stimulates the marrow to produce red cells. It is FDA approved to treat people who have severe anemia who are receiving chemotherapy for nonmyeloid malignancies. Darbepoetin alfa has no direct effect on cancer cells.
Aranesp® Darbepoetin alfa
Dasatinib is FDA approved to treatNewly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.Adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.Pediatric patients 1 year of age and older with Ph+ CML in chronic phase. Pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.Special considerationsTell your doctor if you have any other medical conditions, especially if you have a liver or heart problem or are lactose intolerant.
Sprycel® Dasatinib
Daunorubicin is FDA approved for use in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphoblastic leukemia of children and adults. Daunorubicin causes urine to turn reddish in color, which may stain clothes. This is not blood. It is perfectly normal and lasts for only 1 or 2 days after each dose is given. This medicine often causes a temporary and total loss of hair. After treatment with daunorubicin has ended, normal hair growth should return.
Cerubidine® Daunorubicin
Daunorubicin and cytarabine is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
Vyxeos® Daunorubicin and cytarabine
Decitabine is FDA approved to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia.
Dacogen® Decitabine
Inqovi is FDA approved for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Inqovi® Decitabine and cedazuridine
Deferasirox is FDA approved to remove excess iron that is in the body because of blood transfusions. Deferasirox works by attaching to iron molecules in the body so they can be excreted (removed from the body) in feces.Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. This indication is approved under accelerated approval based on a reduction of liver iron concentrations and serum ferritin levels. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Exjade® Jadenu® Deferasirox
Deferoxamine mesylate is FDA approved to treat people who have acute iron intoxication and of chronic iron overload due to transfusion-dependent anemia.
Desferal® DFO Deferoxamine mesylate
Defibrotide sodium is FDA approved for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
Defitelio® Defibrotide sodium
Denileukin diftitox is FDA approved to treat people who have persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.
Ontak®
Denileukin diftitox
Denileukin diftitox-cxdl is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Denileukin diftitox-cxdl
Denosumab is FDA approved for the prevention of skeletal-related events in patients with multiple myeloma.
Xgeva® Denosumab
Dexamethasone, hydrocortisone, methylprednisolone and prednisone are FDA approved corticosteroids that are used to treat many medical problems, including some kinds of cancer. Side effects needing medical attention: Swelling of feet and ankles; muscle weakness; ulcers or stomach pain or burning; easy bruising; wounds that are slow to heal; dizziness; severe headaches; menstrual problems; blood-sugar problems; blurred or decreased vision or seeing halos around lights; sore throat and fever; depression; mood or mental changes; indigestion; sleeplessness; nervousness or restlessness; weight gain.
Prednisone Decadron® Medrol® Methylprednisolone Dexamethasone
Doxorubicin is FDA approved to treat people who have some kinds of blood cancer, including acute lymphoblastic leukemia, acute myeloblastic leukemia, and Hodgkin and non-Hodgkin lymphoma.
Adriamycin® Doxorubicin
Glasdegib is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.Limitation of Use: Glasdegib has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.
Daurismo® Glasdegib
Hydroxyurea is FDA approved to treat people who have chronic myelocytic leukemia and some other blood cancers, including essential thrombocythemia and polycythemia vera. Hydroxyurea may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Droxia® Hydrea® Hydroxyurea
Liposomal doxorubicin is FDA approved for use in combination with bortezomib to treat patients with myeloma who have not previously received bortezomib and have received at least one prior therapy. See the FDA announcement about drug shortage of Doxil.
Doxil® Liposomal doxorubicin